Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges.
about
Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?Medication-related issues associated with adherence to long-term tyrosine kinase inhibitors for controlling chronic myeloid leukemia: a qualitative studyChronic Myeloid Leukemia in India.Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial.Short overview on the current treatment of chronic myeloid leukemia in chronic phaseCharacterization of Patients with Chronic Myeloid Leukemia Unresponsive to Tyrosine Kinase Inhibitors Who Underwent Allogeneic Hematopoietic Stem Cell TransplantationAssociation between insurance status at diagnosis and overall survival in chronic myeloid leukemia: A population-based study.Factors influencing adherence in CML and ways to improvement: Results of a patient-driven survey of 2546 patients in 63 countries.Symptom Burden and Quality of Life Issues among Patients of Chronic Myeloid Leukemia on Long-term Imatinib TherapyInnovation in hematology. Perspectives: CML 2016Understanding and Challenges in Taking Tyrosine Kinase Inhibitors among Malaysian Chronic Myeloid Leukemia Patients: A Qualitative StudyMobile Health Intervention to Increase Oral Cancer Therapy Adherence in Patients With Chronic Myeloid Leukemia (The REMIND System): Clinical Feasibility and Acceptability Assessment.Non-adherence to cytoreductive and/or antithrombotic drugs is frequent and associated with increased risk of complications in patients with polycythaemia vera or essential thrombocythaemia (OUEST Study).Intentional Nonadherence as a Means to Exert Control.Chronic Myeloid Leukemia-the Promise of Tyrosine Kinase Inhibitor Discontinuation.Dried blood spot sampling of nilotinib in patients with chronic myeloid leukaemia: a comparison with venous blood sampling.Mechanisms of Resistance to Targeted Therapies in Chronic Myeloid Leukemia.Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy.Similar expression profiles in CD34+ cells from chronic phase chronic myeloid leukemia patients with and without deep molecular responses to nilotinib.CML - we are not there yet.The impact of introducing tyrosine kinase inhibitors on chronic myeloid leukemia survival: a population-based study
P2860
Q30242015-20532E71-0B2A-42CB-ACF2-66C54DE64E7CQ33813279-844BFC18-1EA5-49E0-B96A-B32F397C4B3EQ33859551-307C5713-D7C7-471F-B82B-6E4D96A1D74CQ37427140-97F8EE2D-9DDF-4FC9-A07D-F5C69D076B01Q37512201-F89E84B3-B6D9-4011-81C9-3DF0C4A697C9Q37682119-5789950D-85F3-49CF-82F3-A90856252110Q38808692-F7435762-5F85-4601-ADB1-ACAB8C07ACE1Q40294098-BB4ADEC9-DE66-4C3B-BD66-DE5E40C1EAC2Q41601810-BC59137F-59B2-4762-93EE-5CC12CFA5E8AQ42397473-AE162CE9-8A98-4C5C-AA44-31C2AD294944Q42672759-A0A35D9B-1BAF-45C4-8595-D6BBA5191CE7Q47135575-D35E7908-11E8-49F7-B1A9-7BCE8817FA1CQ47300146-CCF60D5B-76B6-4560-8A0C-F0CFEA3335A2Q47333047-FF88E2AB-9A21-4162-8DF1-D43F58758C2AQ47929120-61A85D2F-70AC-41A0-8F40-C25EA3A6A8E6Q48232212-B58F40DC-8BB6-4430-9FB9-0B842C46A2CEQ49833785-5C8008D4-2728-47DB-A557-173C9BE18C66Q49888044-043FD47A-D571-471B-83C8-376AA22A51BBQ52715772-CE98D3CA-28E4-484D-A756-0D105F7A4219Q55034957-5A629F77-AFD1-460C-AD19-514DD9CC2052Q58605235-25286277-0F3E-4E52-83B1-8BCA678F9B45
P2860
Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Measurement of adherence to BC ...... tuation and future challenges.
@en
Measurement of adherence to BC ...... tuation and future challenges.
@nl
type
label
Measurement of adherence to BC ...... tuation and future challenges.
@en
Measurement of adherence to BC ...... tuation and future challenges.
@nl
prefLabel
Measurement of adherence to BC ...... tuation and future challenges.
@en
Measurement of adherence to BC ...... tuation and future challenges.
@nl
P2093
P2860
P1433
P1476
Measurement of adherence to BC ...... ituation and future challenges
@en
P2093
Christina Lofgren
Isabelle Gilloteau
Izabela Kucmin-Bemelmans
Lucien Noens
Marja Hensen
P2860
P304
P356
10.3324/HAEMATOL.2012.082511
P577
2014-03-01T00:00:00Z